N@N

ATLANTA--([ BUSINESS WIRE ])--Holzer Holzer & Fistel, LLC is investigating whether Questcor Pharmaceuticals, Inc. (aQuestcora or the aCompanya) (NASDAQ: QCOR) and/or its officers or directors have violated the federal securities laws. The investigation focuses on whether a series of statements regarding the Companyas business, its prospects and its operations were materially false and misleading at the time they were made. On September 19, 2012, it was revealed to investors that Aetna had issued a Clinical Policy Bulletin stating that it would no longer provide coverage for Questcoras HP Acthar Gel because it believed the product was not amedically necessarya for a number of the conditions for which it was prescribed. Then, on September 24, 2012, Questcor revealed that the U.S. Government was investigating its marketing strategy and potential anticompetitive practices. The price of Questcoras stock fell dramatically following each announcement.

If you purchased Questcor common stock between April 26, 2011 and September 21, 2012 and have questions concerning your legal rights, you are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel Jr., Esq. or Marshall P. Dees, Esq. via email at [ mfistel@holzerlaw.com ], or [ mdees@holzerlaw.com ], or via toll-free telephone at (888) 508-6832.

Holzer Holzer & Fistel, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, [ www.holzerlaw.com ] and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.